RADX

NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Tuesday, April 28, 2026 featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the United States. Representatives from participating companies based in Australia, China, Hong Kong, Portugal, Netherlands, Cayman Islands and France, will respond to questions during formal presentations. The conference is targeted to all categories of investors and analysts interested in international companies. There is no fee for participants to log in, attend live presentations and/or ask qu

6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

Completed enrolment in Phase 2b clinical trial of imaging agent RAD 101 in patients with recurrent brain metastases following earlier announcement of interim data demonstrating concordance with MRI (the primary endpoint) in 90% of evaluable subjects (18/20) Presented initial Phase 0/1 data for RAD 202 at the American Association for Cancer Research demonstrating encouraging tumor uptake and a favorable safety profile in the lowest dose cohort Received positive recommendation from Data and Safety Monitoring Committee (DSMC) to advance RAD 202 to the next dose level Initiated two First-In-Human (FIH) clinical trials for radiotherapeutic assets RV-01 in various tumor types and RAD 402 in adv

6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

177Lu-RAD202 demonstrated encouraging tumor uptake and a favorable safety profile in the lowest dose cohort  Data Safety and Monitoring Committee Recently Approved Advancing 177Lu-RAD202 to Next Highest Dose at 130 mCi SYDNEY, April 20, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that new data from the ongoing Phase 0/1 HEAT trial (NCT06824155), evaluating 177Lu-RAD202, a first-in-class HER2-targeted radiopharmaceutical therapy, will be presented as a poster at the Amer

6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

Interim data to date showed 90% concordance with MRI (the primary endpoint) Clinical trial readout (Primary endpoint) expected in June 2026 Plans to advance RAD 101 into U.S. Phase 3 pivotal trial SYDNEY, April 16, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical needs, today announced that the final patient has been dosed in the U.S. Phase 2b imaging trial (NCT06777433) evaluating RAD 101 in individuals with confirmed recurrent brain metastases from solid tumors of different origins. "Dosing the final patie

6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

SYDNEY, April 08, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that it has received a positive recommendation from the Data Safety and Monitoring Committee (DSMC) to advance its clinical-stage radiotherapeutic asset, 177Lu-RAD202 (RAD202), to the next dose level of 130mCi in the Phase 1 ‘HEAT' clinical trial in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive advanced solid tumors1. The DSMC is a multidisciplinary committee that conducts detailed revie

6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

Data from the interim analysis in Phase 2b trial of RAD101 showed significant and selective tumor uptake in brain metastases, with 90% concordance (Primary Endpoint) with MRI. Partnership ensures sufficient supply of RAD 101 in Phase 3 registrational trial in the U.S. SYDNEY, April 07, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, and Siemens Healthineers, today announced the signing of a supply agreement in which Siemens Healthineers will radiolabel and distribute RAD101 with Fluorine-18 (18F). RAD101

3 - Radiopharm Theranostics Ltd (0001949257) (Issuer)

3 - Radiopharm Theranostics Ltd (0001949257) (Issuer)

3 - Radiopharm Theranostics Ltd (0001949257) (Issuer)

3 - Radiopharm Theranostics Ltd (0001949257) (Issuer)

6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

On track to share data from first two dose levels in 2H 2026 Targeting KLK3 and leveraging the dual emission of Tb161 represents an innovative approach for radiotherapies in Prostate Cancer Preclinical proof-of-concept mouse xenografts demonstrated RAD 402's strong tumor targeting with minimal bone/marrow uptake and expected hepatic clearance SYDNEY, March 27, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that the first patient has been dosed in its first-in-human Phase 1 clinical tria

90% of patients dosed with RAD 101 and evaluable at interim analysis achieved concordance with MRI imaging (the primary endpoint) First five patients with available data from six-month follow-up and biopsy show encouraging trend for Sensitivity and Specificity (secondary objective) Company to host webinar on March 25 at 9:00 am AEDT (Sydney, Melbourne) / Tuesday, March 24 at 6:00 pm EST (U.S.) SYDNEY, Australia, March 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced the second interi

6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

3 - Radiopharm Theranostics Ltd (0001949257) (Issuer)

6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

First radiotherapeutic agent developed by Radiopharm Ventures, the joint venture between Radiopharm Theranostics and MD Anderson Cancer Center  Preclinical animal studies of BetaBart (RV-01) have demonstrated tumor shrinkage and prolonged survival SYDNEY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced the dosing of the first patient in its First-In-Human (FIH) Phase 1/2a clinical trial of 177Lu-Betabart (RV-01). The Phase 1/2a clinical trial is a dose escalation and expansion

6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)